How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol

Impact Factor: 7.689

Blood replacement with nanobiotechnologically engineered hemoglobin and hemoglobin nanocapsules

Advanced Review

Thomas Ming Swi Chang

Published Online: Jun 17 2010

DOI: 10.1002/wnan.95

Full article on Wiley Online Library: HTML PDF

Can't access this content? Tell your librarian.

Abstract Unlike donor red blood cells (RBCs), blood substitutes can be treated to remove infective agents and can be used on the spot or in the ambulance in emergency without the time‐consuming typing and cross‐matching. Donor RBC requires storage at 4° and is only good for 42 days, but blood substitutes can be stored for much longer time. For example, a bovine polyhemoglobin (PolyHb) can be stored at room temperature for more than 1 year. It has been shown as far back as 1957 that artificial RBC can be prepared with ultrathin polymer membranes of nanodimension thickness. To increase the circulation time, the first‐generation engineered hemoglobin (Hb) is formed by using glutaraldehyde to crosslink Hb into soluble nanodimension PolyHb that has been tested clinically in patients. Further extension includes conjugated Hb, intramolecularly crosslinked Hb and recombinant Hb. For certain clinical uses, in addition to engineered Hb, we also need antioxidants to remove oxygen radicals to prevent injury from ischemia reperfusion. Thus, we use nanobiotechnology to prepare second‐generation engineered Hb by assembling Hb together with superoxide dismutase (SOD) and catalase (CAT) to form a nanodimension soluble complex of polyhemoglobin (PolyHb)‐CAT‐SOD. A third generation system is to prepare nanodimension complete artificial RBCs that can circulate for sufficient length of time after infusion. One approach uses lipid vesicles to encapsulate hemoglobin (Hb). Another approach is to use biodegradable polymer‐like polylactic acid or a copolymer of polyethylene glycol‐polylactide (PEG‐PLA) to form the membrane of nanodimension complete artificial RBC (www.artcell.mcgill.ca). WIREs Nanomed Nanobiotechnol 2010 2 418–430 This article is categorized under: Implantable Materials and Surgical Technologies > Nanotechnology in Tissue Repair and Replacement

(a) Upper: Four types of engineered hemoglobin (Hb): (1) Polyhemoglobin (PolyHb) based on nanobiotechnology, (2) conjugated Hb, (3) intramolecularly crosslinked Hb, and (4) recombinant Hb. (b) Lower right: Larger complexes, like PolyHb and conjugated Hb cannot cross the intercellular junctions of the endothelial lining of vascular wall. Lower left: Small single Hb molecules, such as intramolecularly crosslinked Hb and recombinant Hb, can cross and bind and remove the nitric oxide needed for maintaining the normal tone of smooth muscles. This results in the constriction of blood vessels (Reprinted with permission from Ref 5. Copyright 2007 Taylor & Francis).

[ Normal View | Magnified View ]

(Upper left) Polyhemoglobin (PolyHb) formed by nanobiotechnological assembling of hemoglobin (Hb) molecules into soluble nanodimension complex. (Upper right) Soluble PolyHb‐catalase (CAT) containing Hb and CAT. (Lower left) Soluble PolyHb‐CAT‐superoxide dismutase (SOD) containing Hb, CAT, and SOD. (Lower right) PolyHb‐tyrosinase as oxygen carrier that also remove tyrosine to inhibit the growth of melanoma (Reprinted with permission from Ref 5. Copyright 2007 Taylor & Francis).

[ Normal View | Magnified View ]

Effect of superoxide on the stability of: (Upper) PolyHb; (Lower left) crosslinked hemoglobin (Hb) and enzymes obtained directly from red blood cell (RBC) hemolysate; (Lower right) crosslinked Hb and enzymes obtained directly from RBC hemolysate but with more enzymes extracted from RBCs added. (Reprinted with permission from Ref 21. Copyright 2009 Taylor & Francis).

[ Normal View | Magnified View ]

(Top) Amount of membrane material in lipid‐encapsulated Hb (LEH) and polylactic acid (PLA) nano‐red blood cell (RBC); (middle) fate of polylactide membrane in PLA nano‐RBC compared with PLA metabolism; (bottom) hemoglobin (Hb) concentration reported (Reprinted with permission from Ref 5. Copyright 2007 Taylor & Francis).

[ Normal View | Magnified View ]

(a and b) Biodegradable polymeric membrane nanoartificial red blood cell (RBC) with diameters of 80–100 nm containing hemoglobin (Hb) and RBC enzymes (Reprinted with permission from Ref 5. Copyright 2007 Taylor & Francis).

[ Normal View | Magnified View ]

Histology of liver in rats toploaded with nanoartificial red blood cell (RBC) (a), LactRing (b), SF‐Hb (c), polyhemoglobin (PolyHb) (d), or RBC (e). Under light microscope, there was no abnormality in Groups a, b, d, and e. For Group c infused with SF‐Hb, there is hemoglobin (Hb) accumulation and steatmotosis. H&E staining, × 400 (Reprinted with permission from Ref 37. Copyright 2008 Taylor & Francis).

[ Normal View | Magnified View ]

(a) Artificial red blood cell (RBC) with nanodimension thickness nylon‐protein membrane. Spherical in hypotonic solution, becoming 'crenated' in hypertonic solutions. Reversible when moved from one solution to another. (b) An example of assembling of biological molecules to form polyhemoglobin (PolyHb) and conjugated hemoglobin (Hb) in the form of nanodimension thickness membrane for artificial cells (left) or as soluble nanodimension complexes of PolyHb or conjugated Hb (Reprinted with permission from Ref 5. Copyright 2007 Taylor & Francis).

[ Normal View | Magnified View ]

References

Chang, TMS. ‘Hemoglobin Corpuscles’ {Honours Physiology Research Report}, 1957 Medical Library, McGill University (Also reprinted as part of ‘30th Anniversary in Artificial Red Blood Cells Research’). Biomater Artif Cells Artif Organs 1988, 16: 1–9.
Chang, TMS. Semipermeable microcapsules. Science 1964, 146(3643): 524.
Chang, TMS. Artificial Cells (Monograph). Springfield, IL: Charles C. Thomas; 1972 Available at: www.artcell.mcgill.ca.
Chang, TMS. Therapeutic applications of polymeric artificial cells. Nat Rev Drug Discov 2005, 4: 221–235.
Chang, TMS. Monograph on ARTIFICIAL CELLS: Biotechnology, Nanotechnology, Blood Substitutes, Regenerative Medicine, Bioencapsulation, Cell/Stem Cell Therapy. Singapore %26 London: World Science Publisher %26 Imperial College Press; 2007, 1–452. Available at: www.artcell.mcgill.ca.
Chang, TMS. Stabilisation of enzymes by microencapsulation with a concentrated protein solution or by microencapsulation followed by cross‐linking with glutaraldehyde. Biochem Biophys Res Common 1971, 44: 1531–1536.
Perutz, MF. Myoglobin and Hb: role of distal residues in reactions with haem ligands. Trends Biochem Sci 1989, 14: 42–44.
Chang, TMS. Blood Substitutes: Principles, Methods, Products and Clinical Trials. Vol. 1. Basel: Karger; 1997 Available at: www.artcell.mcgill.ca.
Gould, SA, Moss, GS. Clinical development of human polymerized hemoglobin as a blood substitute. World J Surg 1996, 20: 1200–1207.
Moore, EE, Moore, FA, Fabian, TC, Bernard, AC, Fulda, GJ, et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. J Am Coll Surg 2009, 208: 1–13.
Jahr, JS, Mackenzie, C, Pearce, LB, Pitman, A, Greenburg, AG. HBOC‐201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopaedic surgery. J Trauma 2008, 64: 1484–1497.
Olofsson, C, Torbjo, A, Johansson, T, Larsson, S, Nellga, P, et al. A multicenter clinical study of the safety and activity of maleimide‐polyethylene glycol–modified hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology 2006, 105: 1153–1163.
Natanson, C, Kern, SJ, Lurie, P, Banks, SM, Wolfe, SM. Meta‐analysis: risk of myocardial infarction and death: a cell‐free hemoglobin‐based blood substitutes. JAMA 2008, 299: 2304–2312.
Yu, BL, Liu, ZC, Chang, TMS. PolyHb with different percentage of tetrameric Hb and effects on vasoactivity and electrocardiogram. Artif Cells Blood Substit Biotechnol 2006, 34: 159–175.
Yu, B, Raher, MJ, Volpato, GP, Bloch, KD, Ichinose, F, et al. Inhaled nitric oxide enables artificial blood transfusion without hypertension. Circulation 2008, 117: 1982–1990.
Alayash, AI, D`Agnillo, F, Buehler, PW. First‐generation blood substitutes: what have we learned? Biochemical and physiological perspectives. Expert Opin Biol Ther 2007, 7: 665–675.
D`Agnillo, F, Chang, TMS. PolyHb‐superoxide dismutase. Catalase as a blood substitute with antioxidant properties. Nat Biotechnol 1998, 16: 667–671.
Powanda, D, Chang, TMS. Cross‐linked polyHb‐superoxide dismutase‐catalase supplies oxygen without causing blood brain barrier disruption or brain edema in a rat model of transient global brain ischemia‐reperfusion. Artif Cells Blood Substit Biotechnol 2002, 30: 25–42.
Chang, TMS. A nanobiotechnologic therapeutic that transport oxygen and remove oxygen radicals: for stroke, hemorrhagic shock and related conditions. In: Chang, TMS Artificial Cells: Biotechnology, Nanomedicine, Regenerative Medicine, Blood Substitutes, Bioencapsulation and Cell/Stem Cell Therapy. Singapore: World Science Publisher; 2007, 62–92.
Chang, TMS. Nanobiotechnological modification of hemoglobin and enzymes from this laboratory. Biochim Biophys Acta: Proteins and Proteomics 2008, 1784: 1435–1444.
Gu, J, Chang, TMS. Extraction of erythrocyte enzymes for the preparation of polyhemoglobin‐catalase‐superoxide dismutase. Artif Cells Blood Substit Biotechnol 2009, 37: 69–77.
Chang, EJ, Lee, TH, Mun, K. Effects of polyhemoglobin‐antioxidant enzyme complex on ischemia‐reperfusion in kidney. Transplant Proc 2004, 36: 1952–1954.
Buehler, PW, Haney, CR, Gulati, A, Ma, L, Hsia, CJ. Polynitroxyl hemoglobin: a pharmacokinetic study of covalently bound nitroxides to hemoglobin platforms. Free Radic Biol Med 2004, 37: 124–135.
Wong, N, Chang, TMS. Polyhemoglobin‐fibrinogen: a novel blood substitutes with platelet‐like activity for extreme hemodilution. Artif Cells Blood Substit Biotechnol 2007, 35: 481–489.
Yu, BL, Chang, TMS. In vitro and in vivo effects of polyHb–tyrosinase on murine B16F10 melanoma. Melanoma Res 2004, 14: 197–202.
Djordjevich, L, Miller, IF. Synthetic erythrocytes from lipid encapsulated hemoglobin. Exp Hematol 1980, 8: 584.
Phillips, WT, Klipper, RW, Awasthi, VD, Rudolph, AS, Cliff, R, et al. Polyethylene glyco‐modified liposome‐encapsulated hemoglobin: a long circulating red cell substitute. J Pharmacol Exp Ther 1999, 288: 665–670.
Tsuchida,, E, ed. Present and future perspectives. In: Blood Substitutes. Amsterdam: Elsevier; 1998, 267.
Tsuchida, E, Sakai, H, Horinouchi, H, Kobayashi, K. Hemoglobin‐vesicles as a transfusion alternative. Artif Cells Blood Substit Biotechnol 2006, 34: 581–588.
Atoji, T, Aihara, M, Sakai, H, Tsuchida, E, Takeoka, S. Hemoglobin vesicles containing methemoglobin and tyrosine to suppress methemoglobin formation in vitro and in vivo. Bioconjug Chem 2006, 17: 1241–1245.
Chang, TMS. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. J Bioeng 1976, 1: 25–32.
Yu, WP, Chang, TMS. Submicron biodegradable polymer membrane Hb nanocapsules as potential blood substitutes: a preliminary report. Artif Cells Blood Substit Biotechnol 1994, 22: 889–894.
Yu, WP, Chang, TMS. Submicron biodegradable polymer membrane Hb nanocapsules as potential blood substitutes. Artif Cells Blood Substit Biotechnol 1996, 24: 169–184.
Chang, TMS, Powanda, D, Yu, WP. Ultrathin polyethylene‐glycol‐polylactide copolymer membrane nanocapsules containing polymerized Hb and enzymes as nano‐dimension RBC substitutes. Artif Cells Blood Substit Biotechnol 2003, 31: 231–248.
Chang, TMS. Nanotechnology based artificial red blood cells. In: Chang, TMS (monograph). Artificial Cells: Biotechnology, Nanomedicine, Regenerative Medicine, Blood Substitutes, Bioencapsulation and Cell/Stem Cell Therapy. Singapore: World Science Publisher; 2007, 93–128.
Liu, ZC, Chang, TMS. Effects of PEG‐PLA‐nano artificial cells containing hemoglobin on kidney function and renal histology in rats. Artif Cells Blood Substit Biotechnol 2008, 36: 421–430.
Liu, ZC, Chang, TMS. Long term effects on the histology and function of livers and spleens in rats after 33% toploading of PEG‐PLA‐nano artificial red blood cells. Artif Cells Blood Substit Biotechnol 2008, 36: 513–524.
Rameez, S, Alosta, H, Palmer, AF. Biocompatible and biodegradable polymersome encapsulated hemoglobin: a potential oxygen carrier. Bioconjug Chem 2008, 19: 1025–1032.
Rao, S, Harrington, R, Califf, R, Stamler, J. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. J Am Med Assoc 2005, 293: 673–674.
Rao, SV, Jollis, JG, Harrington, RA, Granger, CB, Newby, LK, et al. Blood transfusion in patients with acute coronary syndrome. J Am Med Assoc 2004, 292: 1555–1562.
Artificial cells, blood substitutes and nanomedicine. Public Service Website of the Artificial Cells and Organs Research Centre of McGill University. Available at: www.artcell.mcgill.ca.

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts